Movianto’s expansion into active frozen transport solutions signifies a pivotal advancement in their offerings as a logistics partner for the pharmaceutical and healthcare industries in Europe. Within the Walden Group since 2020, Movianto aims to be the preferred logistics partner by providing services such as temperature-controlled warehouse logistics, transport, and comprehensive solutions like order to cash and procurement services. Their latest gambit involves innovating distribution and delivery capabilities to support the 2024/2025 autumn vaccine and flu campaigns with active frozen transport solutions.
Technological Advancements in Frozen Transport
Introduction of Active Frozen Transport Solutions
The latest development in the UK involves augmenting distribution and delivery capabilities to support the 2024/2025 autumn vaccine and flu campaigns. This enhancement introduces active frozen transport solutions, enabling the transport of vaccines and lifesaving medicines at temperatures as low as -25°C. This marks a departure from the traditional reliance on costly and time-restricted methods using passive shippers and dry ice. The pioneering approach aims to not only maintain but also enhance the efficiency and safety of temperature-sensitive products throughout the supply chain.
Ben Williams, Account Director for Government Contracts at Movianto UK, highlights the transformative benefits that this technological advancement brings to the table. By reducing costs and improving delivery lead times, the active frozen transport solutions provide a more agile and resilient logistics network. This is achieved by configuring existing trailers and the fleet to operate at these low temperatures, allowing direct loading onto trailers straight from temperature-controlled warehouse facilities. The seamless transition ensures that the high standards of pharmaceutical logistics are preserved while adhering to stringent regulatory requirements for cold chain management.
Efficiency and Client Satisfaction
David Evans, Managing Director at Movianto UK, emphasizes that this evolution in logistics is a concerted effort to enhance efficiency and client satisfaction. Supported by the Walden Group, Movianto is part of Europe’s leader in healthcare supply chain solutions. Walden Group offers end-to-end services across the pharmaceutical supply chain, with specialized units handling different aspects such as first-mile transport (Transpharma International), logistics, and value-added services (Movianto), and last-mile solutions (Eurotranspharma). The group’s presence spans 15 countries with around 6,000 employees at over 250 sites. This extensive infrastructure not only solidifies their market presence but also facilitates a robust and coordinated effort in implementing these advanced transport solutions.
The strategic shift towards active frozen transport reflects Movianto’s relentless commitment to adapting and optimizing their services to meet client needs. The implementation of these advanced logistics solutions exemplifies their capability to support critical healthcare campaigns efficiently. This comprehensive backing from Walden Group ensures that Movianto can utilize an integrated approach, combining innovation and operational excellence to deliver reliable and timely services. By being at the forefront of logistics advancements, Movianto is prepared to lead the way in supporting global healthcare initiatives with unparalleled effectiveness.
Comprehensive Service Portfolio
Integrated Supply Chain Solutions
The partnership with Walden Group empowers Movianto to offer an all-encompassing suite of services across the pharmaceutical supply chain. Movianto’s role in providing temperature-controlled warehouse logistics and transport services is complemented by Walden Group’s specialized units that manage different facets of the supply chain. Transpharma International is dedicated to first-mile transport, ensuring that raw materials and initial distribution channels operate seamlessly. This integration across the supply chain guarantees that each stage, from production to distribution, maintains the highest levels of quality control and efficiency.
The inclusion of value-added services provided by Movianto further enhances their standing as a comprehensive logistics partner. These services include order to cash solutions and procurement services, which streamline financial and supply chain management processes. By offering these extensive services, Movianto helps clients navigate the complexities of the pharmaceutical industry with ease. The holistic approach to logistics enables clients to concentrate on their core competencies while entrusting Movianto with the intricacies of supply chain management.
Benefits to Healthcare Campaigns
Movianto’s venture into active frozen transport solutions marks a significant leap in its services for the pharmaceutical and healthcare sectors in Europe. A part of the Walden Group since 2020, Movianto strives to be the go-to logistics partner by offering a wide range of services. These include temperature-controlled warehouse logistics, specialized transport, and comprehensive offerings like order-to-cash processes and procurement services. By pioneering active frozen transport, Movianto aims to revolutionize distribution and delivery methods, especially in preparation for the 2024/2025 autumn vaccine and flu campaigns. This initiative underscores their commitment to maintaining optimal conditions for sensitive medical products, ensuring they reach their destinations safely and efficiently. With this advanced technology, Movianto aims to address the growing needs of the healthcare industry, bolstering its reputation as a reliable logistics provider. Their advancements in cold chain logistics demonstrate their focus on innovation and quality, solidifying their role in the industry.
